Advertisement

Index by author

November 01, 1989; Volume 251,Issue 2

A

  1. Abdallah, E A

    1. Aging does not alter brain muscarinic receptor-mediated phosphoinositide hydrolysis and its inhibition by phorbol esters, tetrodotoxin and receptor desensitization.
      W Surichamorn, E A Abdallah and E E el-Fakahany
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 543-549;

  2. Aceto, J F

    1. Angiotensin II receptor-mediated stimulation of cytosolic-free calcium and inositol phosphates in chick myocytes.
      K M Baker, H A Singer and J F Aceto
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 578-585;

  3. Adair, C G

    1. Pharmacokinetics of naloxone: an insight into the locus of effect on stress-ulceration.
      R L Kleiman-Wexler, C G Adair and K S Ephgrave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 435-438;

  4. Albuquerque, E X

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

  5. Anania, M C

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

  6. Aracava, Y

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

  7. Asano, M

    1. Divergent pharmacological effects of three calmodulin antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), chlorpromazine and calmidazolium, on isometric tension development and myosin light chain phosphorylation in intact bovine tracheal smooth muscle.
      M Asano
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 764-773;

  8. Atchison, W D

    1. Dihydropyridine-sensitive and -insensitive components of acetylcholine release from rat motor nerve terminals.
      W D Atchison
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 672-678;

  9. Audette, C A

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

B

  1. Baker, K M

    1. Angiotensin II receptor-mediated stimulation of cytosolic-free calcium and inositol phosphates in chick myocytes.
      K M Baker, H A Singer and J F Aceto
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 578-585;

  2. Balster, R L

    1. Effects of competitive and noncompetitive N-methyl-D-aspartate (NMDA) antagonists in rats trained to discriminate NMDA from saline.
      J Willetts and R L Balster
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 627-633;

  3. Bazzett, T J

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  4. Berg, T

    1. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis.
      T Berg, E Schlichting, H Ishida and O A Carretero
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 731-734;

  5. Bertalmio, A J

    1. Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis.
      A J Bertalmio and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 455-460;

  6. Bethea, C L

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  7. Blumer, J L

    1. Critical period of phenytoin teratogenic action in the sea urchin, Arbacia punctulata embryo.
      S Estus and J L Blumer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 782-789;

  8. Bonadonna, A M

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  9. Boschero, L

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

  10. Bowden, C R

    1. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
      C R Bowden and C S Marchione
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 599-605;

  11. Breimer, D D

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  12. Budai, D

    1. Opioid-induced prejunctional inhibition of vasoconstriction in the rabbit ear artery: alpha-2 adrenoceptor activation and external calcium.
      D Budai and S P Duckles
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 497-501;

  13. Bunag, R D

    1. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
      L Kerecsen and R D Bunag
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 645-649;

  14. Burstein, S H

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

  15. Bylund, D B

    1. Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype.
      D B Bylund and C Ray-Prenger
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 640-644;

C

  1. Carnes, M

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  2. Carretero, O A

    1. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis.
      T Berg, E Schlichting, H Ishida and O A Carretero
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 731-734;

  3. Chavkin, C

    1. Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
      T L Wimpey, K E Opheim and C Chavkin
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 405-411;

  4. Chen, A D

    1. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
      R J Mandel, A D Chen, D J Connor and L J Thal
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 612-619;

  5. Chi, L G

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

  6. Chiossone, D C

    1. SK&F 104353: selective antagonism of peptidoleukotrine-induced changes in electrolyte transport by rat ileal mucosa in vitro.
      E Elton, D C Chiossone, G P McCafferty, F M Ryan and P L Smith
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 484-489;

  7. Clark, J A

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;

  8. Connor, D J

    1. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
      R J Mandel, A D Chen, D J Connor and L J Thal
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 612-619;

  9. Coscia, C J

    1. A mu-specific opioid peptide agonist increases excitability of pyramidal neurons in untreated and receptor up-regulated hippocampus.
      A M Moudy, C J Coscia and M B Laskowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 536-542;

  10. Cox, P G

    1. Renal handling of salicyluric acid in the isolated perfused rat kidney: evidence for accumulation in tubular cells.
      P G Cox, W M Moons, F G Russel and C A van Ginneken
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 750-755;

  11. Coy, D H

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

  12. Cubeddu, L X

    1. Phorbol esters and D2-dopamine receptors.
      L X Cubeddu, T W Lovenberg, I S Hoffman and R K Talmaciu
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 687-693;

D

  1. de Boer, A G

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  2. Delen, F M

    1. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
      F J Ehlert, F M Delen, S H Yun, D J Friedman and D W Self
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 660-671;

  3. Delle Fave, G

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

  4. Dennis, T

    1. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity.
      T Dennis, A Fournier, S St Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 718-725;

  5. De Vry, J

    1. Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol.
      J De Vry, I Donselaar and J M Van Ree
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 735-740;

  6. Donselaar, I

    1. Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol.
      J De Vry, I Donselaar and J M Van Ree
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 735-740;

  7. Doyle, S A

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

  8. Duckles, S P

    1. Opioid-induced prejunctional inhibition of vasoconstriction in the rabbit ear artery: alpha-2 adrenoceptor activation and external calcium.
      D Budai and S P Duckles
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 497-501;

E

  1. Eaton, R C

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  2. Edelson, M

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;

  3. Ehlert, F J

    1. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
      F J Ehlert, F M Delen, S H Yun, D J Friedman and D W Self
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 660-671;

  4. el-Fakahany, E E

    1. Aging does not alter brain muscarinic receptor-mediated phosphoinositide hydrolysis and its inhibition by phorbol esters, tetrodotoxin and receptor desensitization.
      W Surichamorn, E A Abdallah and E E el-Fakahany
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 543-549;

  5. Elfarra, A A

    1. Cysteine S-conjugates may act as kidney-selective prodrugs: formation of 6-mercaptopurine by the renal metabolism of S-(6-purinyl)-L-cysteine.
      I Y Hwang and A A Elfarra
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 448-454;

  6. Elton, E

    1. SK&F 104353: selective antagonism of peptidoleukotrine-induced changes in electrolyte transport by rat ileal mucosa in vitro.
      E Elton, D C Chiossone, G P McCafferty, F M Ryan and P L Smith
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 484-489;

  7. Ephgrave, K S

    1. Pharmacokinetics of naloxone: an insight into the locus of effect on stress-ulceration.
      R L Kleiman-Wexler, C G Adair and K S Ephgrave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 435-438;

  8. Escalante, B A

    1. Effect of synthesis inhibitors of thromboxane A2 and prostaglandin E2 on the regulation of sodium and water.
      J L Reyes, E Meléndez, B A Escalante and M C Namorado
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 694-699;

  9. Estus, S

    1. Critical period of phenytoin teratogenic action in the sea urchin, Arbacia punctulata embryo.
      S Estus and J L Blumer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 782-789;

F

  1. Follmer, C H

    1. Amiodarone blocks calcium current in single guinea pig ventricular myocytes.
      M Nishimura, C H Follmer and D H Singer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 650-659;

  2. Fournier, A

    1. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity.
      T Dennis, A Fournier, S St Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 718-725;

  3. Friedman, D J

    1. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
      F J Ehlert, F M Delen, S H Yun, D J Friedman and D W Self
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 660-671;

  4. Friedman, E

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  5. Frye, J W

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

  6. Furukawa, T

    1. Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes.
      T Furukawa, Y Tsujimura, K Kitamura, H Tanaka and Y Habuchi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 756-763;

G

  1. Garrick, T

    1. Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
      R L Stephens, T Garrick, H Weiner and Y Taché
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 524-530;

  2. Gepp, R T

    1. Development and application of a radioimmunoassay for physostigmine.
      H G Meyer, B J Lukey, R T Gepp, M P McCluskey and C N Lieske
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 606-611;

  3. Gerber, J G

    1. Role of adenosine in the gastric blood flow response to pentagastrin in the rat.
      J G Gerber and P H Guth
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 550-556;

  4. Gillis, R A

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  5. Gistrak, M A

    1. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
      M A Gistrak, D Paul, E F Hahn and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 469-476;

  6. Glavin, G B

    1. Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion.
      G B Glavin
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 726-730;

  7. Guth, P H

    1. Role of adenosine in the gastric blood flow response to pentagastrin in the rat.
      J G Gerber and P H Guth
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 550-556;

H

  1. Habuchi, Y

    1. Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes.
      T Furukawa, Y Tsujimura, K Kitamura, H Tanaka and Y Habuchi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 756-763;

  2. Hahn, E F

    1. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
      M A Gistrak, D Paul, E F Hahn and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 469-476;

  3. Halushka, P V

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  4. Hamosh, P

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  5. Hanson, R C

    1. The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction.
      L Noronha-Blob, V C Lowe, J S Peterson and R C Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 586-593;

  6. Harnett, K M

    1. Effects of Bay o 2752, a hypocholesterolemic agent, on intestinal taurocholate absorption and cholesterol esterification.
      K M Harnett, C T Walsh and L H Zhang
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 502-509;

  7. Hashimoto, N

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  8. Heijligers-Feijen, C D

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  9. Hersh, B

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;

  10. Hoffman, I S

    1. Phorbol esters and D2-dopamine receptors.
      L X Cubeddu, T W Lovenberg, I S Hoffman and R K Talmaciu
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 687-693;

  11. Hong, E K

    1. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice.
      E K Hong and A E Takemori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 594-598;

  12. Hori, R

    1. Effect of various chemical modifiers on H+ coupled transport of cephradine via dipeptide carriers in rabbit intestinal brush-border membranes: role of histidine residues.
      M Kato, H Maegawa, T Okano, K Inui and R Hori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 745-749;

  13. Hull, E M

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  14. Hull, K

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

  15. Hunter, S A

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

  16. Hwang, I Y

    1. Cysteine S-conjugates may act as kidney-selective prodrugs: formation of 6-mercaptopurine by the renal metabolism of S-(6-purinyl)-L-cysteine.
      I Y Hwang and A A Elfarra
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 448-454;

I

  1. Inatomi, N

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  2. Inturrisi, C E

    1. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
      D Paul, K M Standifer, C E Inturrisi and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 477-483;

  3. Inui, K

    1. Effect of various chemical modifiers on H+ coupled transport of cephradine via dipeptide carriers in rabbit intestinal brush-border membranes: role of histidine residues.
      M Kato, H Maegawa, T Okano, K Inui and R Hori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 745-749;

  4. Ishida, H

    1. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis.
      T Berg, E Schlichting, H Ishida and O A Carretero
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 731-734;

  5. Itoh, Z

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  6. Iwamoto, E T

    1. Antinociception after nicotine administration into the mesopontine tegmentum of rats: evidence for muscarinic actions.
      E T Iwamoto
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 412-421;

J

  1. Jensen, R T

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

K

  1. Kaiser, I I

    1. Pharmacologic experiments on the interaction between crotoxin and the mammalian neuromuscular junction.
      S Trivedi, I I Kaiser, M Tanaka and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 490-496;

  2. Kato, M

    1. Effect of various chemical modifiers on H+ coupled transport of cephradine via dipeptide carriers in rabbit intestinal brush-border membranes: role of histidine residues.
      M Kato, H Maegawa, T Okano, K Inui and R Hori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 745-749;

  3. Katz, L B

    1. Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during daily aspirin administration without altering the anti-inflammatory or analgesic efficacy of aspirin.
      L B Katz and D A Shriver
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 774-781;

  4. Kellar, K J

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  5. Kerecsen, L

    1. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
      L Kerecsen and R D Bunag
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 645-649;

  6. Kitamura, K

    1. Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes.
      T Furukawa, Y Tsujimura, K Kitamura, H Tanaka and Y Habuchi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 756-763;

  7. Kitzen, J M

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

  8. Kleiman-Wexler, R L

    1. Pharmacokinetics of naloxone: an insight into the locus of effect on stress-ulceration.
      R L Kleiman-Wexler, C G Adair and K S Ephgrave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 435-438;

  9. Knapp, D R

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  10. Koop, D R

    1. Identification and induction of cytochromes P450, P450IIE1 and P450IA1 in rabbit bone marrow.
      G G Schnier, C L Laethem and D R Koop
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 790-796;

  11. Kraemer, R

    1. Neutrophils delay functional recovery of the post-hypoxic heart of the rabbit.
      R Kraemer and K M Mullane
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 620-626;

  12. Kunimoto, K

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

L

  1. Laethem, C L

    1. Identification and induction of cytochromes P450, P450IIE1 and P450IA1 in rabbit bone marrow.
      G G Schnier, C L Laethem and D R Koop
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 790-796;

  2. Lasdun, A

    1. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
      A Lasdun, S Reznik, C J Molineaux and M Orlowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 439-447;

  3. Laskowski, M B

    1. A mu-specific opioid peptide agonist increases excitability of pyramidal neurons in untreated and receptor up-regulated hippocampus.
      A M Moudy, C J Coscia and M B Laskowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 536-542;

  4. Latham, V

    1. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
      S H Burstein, C A Audette, S A Doyle, K Hull, S A Hunter and V Latham
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 531-535;

  5. Lieske, C N

    1. Development and application of a radioimmunoassay for physostigmine.
      H G Meyer, B J Lukey, R T Gepp, M P McCluskey and C N Lieske
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 606-611;

  6. Liu, L

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;

  7. Lovenberg, T W

    1. Phorbol esters and D2-dopamine receptors.
      L X Cubeddu, T W Lovenberg, I S Hoffman and R K Talmaciu
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 687-693;

  8. Lowe, V C

    1. The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction.
      L Noronha-Blob, V C Lowe, J S Peterson and R C Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 586-593;

  9. Lucchesi, B R

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

  10. Lukey, B J

    1. Development and application of a radioimmunoassay for physostigmine.
      H G Meyer, B J Lukey, R T Gepp, M P McCluskey and C N Lieske
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 606-611;

  11. Lynch, J J

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

M

  1. Maegawa, H

    1. Effect of various chemical modifiers on H+ coupled transport of cephradine via dipeptide carriers in rabbit intestinal brush-border membranes: role of histidine residues.
      M Kato, H Maegawa, T Okano, K Inui and R Hori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 745-749;

  2. Mais, D E

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  3. Maki, Y

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  4. Malik, K U

    1. Influence of protein kinase C activators on vascular tone and adrenergic neuroeffector events in the isolated rat kidney.
      E Sehic and K U Malik
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 634-639;

  5. Mandal, A K

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  6. Mandel, R J

    1. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
      R J Mandel, A D Chen, D J Connor and L J Thal
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 612-619;

  7. Maragoudakis, M E

    1. Antiangiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system.
      M E Maragoudakis, M Sarmonika and M Panoutsacopoulou
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 679-682;

  8. Marchione, C S

    1. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
      C R Bowden and C S Marchione
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 599-605;

  9. Maslowski, R J

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  10. Masuda, A

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  11. Mathôt, R A

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  12. Mayeux, P R

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  13. McCafferty, G P

    1. SK&F 104353: selective antagonism of peptidoleukotrine-induced changes in electrolyte transport by rat ileal mucosa in vitro.
      E Elton, D C Chiossone, G P McCafferty, F M Ryan and P L Smith
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 484-489;

  14. McCluskey, M P

    1. Development and application of a radioimmunoassay for physostigmine.
      H G Meyer, B J Lukey, R T Gepp, M P McCluskey and C N Lieske
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 606-611;

  15. Meléndez, E

    1. Effect of synthesis inhibitors of thromboxane A2 and prostaglandin E2 on the regulation of sodium and water.
      J L Reyes, E Meléndez, B A Escalante and M C Namorado
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 694-699;

  16. Meyer, H G

    1. Development and application of a radioimmunoassay for physostigmine.
      H G Meyer, B J Lukey, R T Gepp, M P McCluskey and C N Lieske
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 606-611;

  17. Molineaux, C J

    1. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
      A Lasdun, S Reznik, C J Molineaux and M Orlowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 439-447;

  18. Moons, W M

    1. Renal handling of salicyluric acid in the isolated perfused rat kidney: evidence for accumulation in tubular cells.
      P G Cox, W M Moons, F G Russel and C A van Ginneken
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 750-755;

  19. Morinelli, T A

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  20. Moudy, A M

    1. A mu-specific opioid peptide agonist increases excitability of pyramidal neurons in untreated and receptor up-regulated hippocampus.
      A M Moudy, C J Coscia and M B Laskowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 536-542;

  21. Mullane, K M

    1. Neutrophils delay functional recovery of the post-hypoxic heart of the rabbit.
      R Kraemer and K M Mullane
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 620-626;

N

  1. Namorado, M C

    1. Effect of synthesis inhibitors of thromboxane A2 and prostaglandin E2 on the regulation of sodium and water.
      J L Reyes, E Meléndez, B A Escalante and M C Namorado
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 694-699;

  2. Nishimura, M

    1. Amiodarone blocks calcium current in single guinea pig ventricular myocytes.
      M Nishimura, C H Follmer and D H Singer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 650-659;

  3. Noronha-Blob, L

    1. The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction.
      L Noronha-Blob, V C Lowe, J S Peterson and R C Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 586-593;

O

  1. Oatis, J E

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  2. Okano, T

    1. Effect of various chemical modifiers on H+ coupled transport of cephradine via dipeptide carriers in rabbit intestinal brush-border membranes: role of histidine residues.
      M Kato, H Maegawa, T Okano, K Inui and R Hori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 745-749;

  3. Okwu, A K

    1. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist.
      T A Morinelli, J E Oatis, A K Okwu, D E Mais, P R Mayeux, A Masuda, D R Knapp and P V Halushka
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 557-562;

  4. Omura, S

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  5. Opheim, K E

    1. Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
      T L Wimpey, K E Opheim and C Chavkin
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 405-411;

  6. Orlowski, M

    1. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
      A Lasdun, S Reznik, C J Molineaux and M Orlowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 439-447;

P

  1. Panoutsacopoulou, M

    1. Antiangiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system.
      M E Maragoudakis, M Sarmonika and M Panoutsacopoulou
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 679-682;

  2. Pasternak, G W

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;
    2. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
      M A Gistrak, D Paul, E F Hahn and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 469-476;
    3. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
      D Paul, K M Standifer, C E Inturrisi and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 477-483;

  3. Paul, D

    1. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
      M A Gistrak, D Paul, E F Hahn and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 469-476;
    2. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
      D Paul, K M Standifer, C E Inturrisi and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 477-483;

  4. Peterson, J S

    1. The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction.
      L Noronha-Blob, V C Lowe, J S Peterson and R C Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 586-593;

  5. Piechowski, R A

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  6. Pineo, S V

    1. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
      A K Mandal, K J Kellar, E Friedman, S V Pineo, P Hamosh and R A Gillis
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 563-570;

  7. Price, M

    1. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.
      J A Clark, L Liu, M Price, B Hersh, M Edelson and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 461-468;

Q

  1. Quirion, R

    1. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity.
      T Dennis, A Fournier, S St Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 718-725;

R

  1. Ray-Prenger, C

    1. Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype.
      D B Bylund and C Ray-Prenger
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 640-644;

  2. Raynor, K

    1. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain.
      K Raynor and T Reisine
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 510-517;

  3. Reisine, T

    1. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain.
      K Raynor and T Reisine
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 510-517;

  4. Reyes, J L

    1. Effect of synthesis inhibitors of thromboxane A2 and prostaglandin E2 on the regulation of sodium and water.
      J L Reyes, E Meléndez, B A Escalante and M C Namorado
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 694-699;

  5. Reznik, S

    1. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
      A Lasdun, S Reznik, C J Molineaux and M Orlowski
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 439-447;

  6. Rittenhouse, P A

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  7. Rozental, R

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

  8. Rudin, M

    1. Dihydropyridine calcium antagonists reduce the consumption of high-energy phosphates in the rat brain. A study using combined 31P/1H magnetic resonance spectroscopy and 31P saturation transfer.
      M Rudin and A Sauter
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 700-706;

  9. Russel, F G

    1. Renal handling of salicyluric acid in the isolated perfused rat kidney: evidence for accumulation in tubular cells.
      P G Cox, W M Moons, F G Russel and C A van Ginneken
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 750-755;

  10. Ryan, F M

    1. SK&F 104353: selective antagonism of peptidoleukotrine-induced changes in electrolyte transport by rat ileal mucosa in vitro.
      E Elton, D C Chiossone, G P McCafferty, F M Ryan and P L Smith
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 484-489;

S

  1. Sarmonika, M

    1. Antiangiogenic action of heparin plus cortisone is associated with decreased collagenous protein synthesis in the chick chorioallantoic membrane system.
      M E Maragoudakis, M Sarmonika and M Panoutsacopoulou
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 679-682;

  2. Satoh, H

    1. An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.
      N Inatomi, H Satoh, Y Maki, N Hashimoto, Z Itoh and S Omura
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 707-712;

  3. Sauter, A

    1. Dihydropyridine calcium antagonists reduce the consumption of high-energy phosphates in the rat brain. A study using combined 31P/1H magnetic resonance spectroscopy and 31P saturation transfer.
      M Rudin and A Sauter
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 700-706;

  4. Sawyer, B D

    1. Glutamate receptors of the N-methyl-D-aspartate subtype in the myenteric plexus of the guinea pig ileum.
      H E Shannon and B D Sawyer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 518-523;

  5. Scaletta, L L

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  6. Schlichting, E

    1. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylaxis or acute pancreatitis.
      T Berg, E Schlichting, H Ishida and O A Carretero
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 731-734;

  7. Schnier, G G

    1. Identification and induction of cytochromes P450, P450IIE1 and P450IA1 in rabbit bone marrow.
      G G Schnier, C L Laethem and D R Koop
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 790-796;

  8. Scoble, G T

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

  9. Sehic, E

    1. Influence of protein kinase C activators on vascular tone and adrenergic neuroeffector events in the isolated rat kidney.
      E Sehic and K U Malik
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 634-639;

  10. Self, D W

    1. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
      F J Ehlert, F M Delen, S H Yun, D J Friedman and D W Self
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 660-671;

  11. Severi, C

    1. Pharmacological characterization of [Leu-13-psi-CH2NH-Leu14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells.
      C Severi, D H Coy, R T Jensen, L Boschero, M C Anania and G Delle Fave
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 713-717;

  12. Shannon, H E

    1. Glutamate receptors of the N-methyl-D-aspartate subtype in the myenteric plexus of the guinea pig ileum.
      H E Shannon and B D Sawyer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 518-523;

  13. Shriver, D A

    1. Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during daily aspirin administration without altering the anti-inflammatory or analgesic efficacy of aspirin.
      L B Katz and D A Shriver
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 774-781;

  14. Simpson, L L

    1. Pharmacologic experiments on the interaction between crotoxin and the mammalian neuromuscular junction.
      S Trivedi, I I Kaiser, M Tanaka and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 490-496;

  15. Singer, D H

    1. Amiodarone blocks calcium current in single guinea pig ventricular myocytes.
      M Nishimura, C H Follmer and D H Singer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 650-659;

  16. Singer, H A

    1. Angiotensin II receptor-mediated stimulation of cytosolic-free calcium and inositol phosphates in chick myocytes.
      K M Baker, H A Singer and J F Aceto
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 578-585;

  17. Smith, P L

    1. SK&F 104353: selective antagonism of peptidoleukotrine-induced changes in electrolyte transport by rat ileal mucosa in vitro.
      E Elton, D C Chiossone, G P McCafferty, F M Ryan and P L Smith
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 484-489;

  18. Standifer, K M

    1. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
      D Paul, K M Standifer, C E Inturrisi and G W Pasternak
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 477-483;

  19. Stephens, R L

    1. Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
      R L Stephens, T Garrick, H Weiner and Y Taché
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 524-530;

  20. St Pierre, S

    1. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity.
      T Dennis, A Fournier, S St Pierre and R Quirion
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 718-725;

  21. Surichamorn, W

    1. Aging does not alter brain muscarinic receptor-mediated phosphoinositide hydrolysis and its inhibition by phorbol esters, tetrodotoxin and receptor desensitization.
      W Surichamorn, E A Abdallah and E E el-Fakahany
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 543-549;

  22. Swanson, K L

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

T

  1. Taché, Y

    1. Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
      R L Stephens, T Garrick, H Weiner and Y Taché
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 524-530;

  2. Takemori, A E

    1. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice.
      E K Hong and A E Takemori
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 594-598;

  3. Talmaciu, R K

    1. Phorbol esters and D2-dopamine receptors.
      L X Cubeddu, T W Lovenberg, I S Hoffman and R K Talmaciu
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 687-693;

  4. Tanaka, H

    1. Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes.
      T Furukawa, Y Tsujimura, K Kitamura, H Tanaka and Y Habuchi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 756-763;

  5. Tanaka, M

    1. Pharmacologic experiments on the interaction between crotoxin and the mammalian neuromuscular junction.
      S Trivedi, I I Kaiser, M Tanaka and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 490-496;

  6. Thal, L J

    1. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
      R J Mandel, A D Chen, D J Connor and L J Thal
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 612-619;

  7. Thompson, J T

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  8. Trivedi, S

    1. Pharmacologic experiments on the interaction between crotoxin and the mammalian neuromuscular junction.
      S Trivedi, I I Kaiser, M Tanaka and L L Simpson
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 490-496;

  9. Tsujimura, Y

    1. Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes.
      T Furukawa, Y Tsujimura, K Kitamura, H Tanaka and Y Habuchi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 756-763;

U

  1. Uprichard, A C

    1. Celiprolol does not protect against ventricular tachycardia or sudden death in the conscious canine: a comparison with pindolol in assessing the role of intrinsic sympathomimetic activity.
      A C Uprichard, L G Chi, J M Kitzen, J J Lynch, J W Frye and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 571-577;

V

  1. van Bezooijen, C F

    1. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
      C F van Bezooijen and R M van Oorschot
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 683-686;

  2. van Bree, J B

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  3. Van de Kar, L D

    1. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5-HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion.
      L D Van de Kar, M Carnes, R J Maslowski, A M Bonadonna, P A Rittenhouse, K Kunimoto, R A Piechowski and C L Bethea
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 428-434;

  4. van Ginneken, C A

    1. Renal handling of salicyluric acid in the isolated perfused rat kidney: evidence for accumulation in tubular cells.
      P G Cox, W M Moons, F G Russel and C A van Ginneken
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 750-755;

  5. van Hoogdalem, E J

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  6. van Oorschot, R M

    1. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
      C F van Bezooijen and R M van Oorschot
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 683-686;

  7. Van Ree, J M

    1. Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol.
      J De Vry, I Donselaar and J M Van Ree
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 735-740;

  8. Verhoef, J C

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

W

  1. Wackwitz, A T

    1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
      E J van Hoogdalem, C D Heijligers-Feijen, R A Mathôt, A T Wackwitz, J B van Bree, J C Verhoef, A G de Boer and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 741-744;

  2. Walsh, C T

    1. Effects of Bay o 2752, a hypocholesterolemic agent, on intestinal taurocholate absorption and cholesterol esterification.
      K M Harnett, C T Walsh and L H Zhang
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 502-509;

  3. Warner, R K

    1. D2/D1 ratio in the medial preoptic area affects copulation of male rats.
      E M Hull, R K Warner, T J Bazzett, R C Eaton, J T Thompson and L L Scaletta
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 422-427;

  4. Weiner, H

    1. Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
      R L Stephens, T Garrick, H Weiner and Y Taché
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 524-530;

  5. Willetts, J

    1. Effects of competitive and noncompetitive N-methyl-D-aspartate (NMDA) antagonists in rats trained to discriminate NMDA from saline.
      J Willetts and R L Balster
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 627-633;

  6. Wimpey, T L

    1. Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
      T L Wimpey, K E Opheim and C Chavkin
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 405-411;

  7. Wonnacott, S

    1. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine.
      R Rozental, Y Aracava, G T Scoble, K L Swanson, S Wonnacott and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 395-404;

  8. Woods, J H

    1. Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis.
      A J Bertalmio and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 455-460;

Y

  1. Yun, S H

    1. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
      F J Ehlert, F M Delen, S H Yun, D J Friedman and D W Self
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 660-671;

Z

  1. Zhang, L H

    1. Effects of Bay o 2752, a hypocholesterolemic agent, on intestinal taurocholate absorption and cholesterol esterification.
      K M Harnett, C T Walsh and L H Zhang
      Journal of Pharmacology and Experimental Therapeutics November 1989, 251 (2) 502-509;
Back to top

In this issue

Advertisement